Life Sciences Archive » June, 2015

Life Sciences - June, 2015

312 articles

• Indirect Buyers Decertified In Wellbutrin Pay-For-Delay Suit
• Apotex To Pay AstraZeneca $98M For Prilosec IP Infringement
• Kaye Scholer Brings 2 Corporate Partners From Katten
• Pharma, Medical Device Cos. Paid $6.5B To Doctors In 2014
• Amarin Not Backing Down In Free Speech Suit Against FDA
• Purdue Halts FDA Review Of Abuse-Resistant OxyContin Label
• Nexium Buyers Say 3rd Circ.'s Lamictal Ruling Backs New Trial
• US Demands Up To $3.35B From Novartis In FCA Suit
• New HHS OIG Unit To Specialize In Fines, Exclusions
• The Playful, Plainspoken Prose Of Justice Elena Kagan
• Justice Thomas Lets His Dissents Do The Talking
• FTC, Fla. Sue Lifewatch For Telemarketing Abuse On Elderly
• Calif. Gov. Signs Law Limiting Vaccination Exemptions
• Cephalon Hit With Latest Pay-For-Delay Generic Provigil Row
• How Drug Cos. Can Minimize Risks Of 'Right To Try' Laws
• Your Advance Conflict Waiver May Be A Conflict Creator
• An 'Exceptional Case' One Year After Octane: Part 1
• The 15 Biggest High Court Decisions Of The Past 15 Years
• Boutiques Wipe The Supreme Court Floor With BigLaw Rivals
• Supreme Court Ends Term Sharply Divided
• Justices Pen More Dissents To Show Votes Aren't Political
• Janssen Ignored Nerve Damage Risk Of Levaquin, Suit Claims
• Three Justices Trusted With Most Controversial Opinions
• Justices Won't Hear Athena's Appeal In Eyelash Product Suit
• Celgene Forms $1B Collaboration With Juno Therapeutics
• FDA Must Cough Up Gilead Hep C Docs, Health Groups Say
• Top 15 High Court Class Action Rulings Of The Past 15 Years
• Corporate Attys Want More High Court Action After Slow Term
• Recent Rulings Shed Light On Fed. Circ's Approach To Teva
• Honigman Scores Ex-Takeda IP Counsel, Paul Hastings Atty
• Goodwin Guides AMAG's $700M Buy Of Stem Cell Bank
• Post-Grant Challenges In Life Sciences: A Midyear Assessment
• Rescue Remedy Maker Pares Down False Ad Class Action
• 3rd Circ. Ruling Isn't Last Word On Noncash Pay-For-Delay
• Bristol-Myers Inks 208K-SF Mass. Lease With REIT Alexandria
• Medtronic Gets Doc's Heart Valve Patent Nixed In AIA Review
• Ex-OtisMed CEO Gets 2 Years For Illegally Shipping Devices
• 5 IPOs Look To Raise $677M Before Long Holiday Weekend
• Medtronic Calls For Gray Reed To Be Forced Off Patent Suit
• Provigil Buyers Ask Judge To Reconsider Class Cert. Denial
• AbbVie Fights FTC's Quick Appeal Bid In Pay-For-Delay Case
• Tyco Faces Leaner Suit Over Eli Lilly Warehouse Heist
• Kythera Investor Challenges $2B Sale To Allergan
• 3rd Circ. Says Cash Not Key For Pay-For-Delay Suits
• The Top 3 New Do's And Don'ts For Law Firm Websites
• Grooming Lessons For Biotech From Abercrombie & Fitch
• FDA Warns Noven's ADHD Patch Can Cause Skin Disfiguration
• FDA Panel To Mull Essure Implant Safety Amid Death Reports
• Brazil Fines Eli Lilly $11.8M For Sham Patent Litigation
• Zoloft Plaintiffs Want Pfizer Expert Booted For Retractions
• Calif. Lawmakers OK Law Ending Vaccination Exemption
• Deals Rumor Mill: Valeant, Zoetis, Aetna, Total
• Not So Fast-Track: More Work To Do In TPP Talks
• Supplement Co. Says Atty Hid Info On Class Rep
• NLRB Clears Fresenius' Firing Of Vulgar Pro-Union Worker
• VC-Backed Glaukos Beats Expectations With $108M IPO
• PE-Backed Diagnostic Imaging Co. Lantheus Misses IPO Target
• 4 Life Science Innovations That Give Life To Patent Growth
• Allergan Says Venture Fund's AIA Petition Is 'Extortion'
• Your Future Tech Clients Would Like A Word With You
• Blue Cross Accuses Boehringer, Teva Of Pay-For-Delay Deal
• House Committee OKs $153B HHS, Labor, Ed Spending Bill
• Drug Cos. Escape Suit Claiming They Inflated Eye Drop Doses
• Pharmacies, Patients Ask 3rd Circ. For Fees In ERISA Case
• 9th Circ. Nixes Class In False Ad Suit Over Nutrition Drink
• Bluebird Stock Offering Lands $500M To Fund Drug Pipeline
• Ferring Sues Actavis Over Generic Blood Loss Drug
• Kirkland Fights DQ Recommendation In Teva Takeover Bid
• Zimmer's $14B Biomet Buy Completed After FTC Gives The OK
• Insolvent Aussie Pharma Sued Over Painkiller's Flop
• Glaucoma Implant Maker Glaukos Boosts IPO Target
• Chinese Medical Equipment Lessor Seeks $546M In HK IPO
• 11th Circ. Doesn't Corral Small-Dollar Class Actions
• The Global Hot Spots Of 2015
• Law360 Reveals The Global 20 Firms Of 2015
• The 5 Firms That Made The Biggest Global Gains
• Ambitious Global Firms Must Have Roots In These Cities
• FDA Goes On Offense In Amarin's Free Speech Suit
• Branch Law Firm Says Arbitration Args Taken Out Of Context
• TTAB Overturns Rejection Of Eli Lilly Diabetes Product Mark
• Hagens Berman, Grunenthal To Settle Time-Barred Suits
• Fed. Circ. Says Pfizer's Celebrex IP Double-Patented
• Sheller Can't Show Injury In Risperdal Fight, FDA Says
• Novartis Hit With Gleevec Sham Litigation Class Action
• OIG Targets Part D Fraud One Week After National Sweep
• Calif. Attys Can Rep Marijuana Dispensaries, SF Bar Says
• Allergan Pulled 'Hard Switch' To Block Generics, Unions Say
• Congress Has To Beat The Clock For 21st Century Cures Act
• Calif. High Court's Cipro Decision Is Problematic
• Abbott Accused Of Withholding Docs In Whistleblower Suit
• High Court Rejects Appeal Over Patent Maintenance Fees
• Australian Gene Therapy Biotech Benitec Eyes $70M US IPO
• Expert Must Show Docs In Reed Smith Atty Paxil Suicide Suit
• FCC Asked To Lift Ultra-Wideband Restrictions
• AbbVie Fights FTC Discovery Expansion In Pay-For-Delay Suit
• CVC-Led Group Picks Up Controlling Alvogen Stake
• Conkwest Looks To Draw $173M In Latest Cancer-Focused IPO
• High Court Won't Review Inequitable Conduct Standards
• McGuireWoods Nabs Real Estate Pro To Grow London Office
• Prenatal Diagnostics Co. Natera Sets Terms For $100M IPO
• Utah — The Latest Battleground In Resale Price Maintenance
• Merck Nixes Some Actions in Vioxx Securities Fraud Battle
• GNC Again Dodges Class Action Over Health Supplement Ads
• Roxane Can Fix Arguments In Jazz's Xyrem Patent Suit
• FDA Patent Rule Has Brands, Generics In War Of Words
• Taxation With Representation: Wachtell, Latham, Cravath
• Deals Rumor Mill: Martha Stewart Living, Synlab, Novolex
• Egenix Gets Nod For $4M Auction Led by Stalking Horse
• MDL Judge Urged To Move Ethicon, Bard Mesh Suits To Philly
• Pneumonia Drug Developer Nabriva Eyes $92M IPO
• Teva Takes Mylan Stake Amid Takeover Dispute
• Biz Software Co. Mindbody Hits Target With $100.1M IPO
• Insights Into HRSA's Proposed 340B Program Rule
• A New Drug Pricing Environment In China
• Why Lateral Candidacies Fail
• FDA Finalizes Controversial Policies On Pill Shapes, Sizes
• Considering Drug Policies After Colo. High Court Ruling
• One Year After Alice: Was It The Right Medicine?
• ClearCorrect Gets USPTO To Re-Examine Invisalign Patents
• Fed. Circ. Axes Teva MS Drug Patent In High Court Remand
• In $700M DOJ Sweep, Medicare Part D Fraud Stands Out
• FDA Targets Counterfeit Drug Websites In Global Sweep
• Hundreds Charged In $712M Medicare Fraud Sweep
• 2 Minority Views From The Top Of BigLaw
• Custom Joint Co. ConforMIS Prepares For Up To $144M IPO
• House Passes Bill To Repeal ACA Medical Device Tax
• Lumenis Ltd. To Be Acquired By XIO In $510M Buyout
• Canada Unveils Proposed IP Competition Guidelines
• Judge OKs $1.2B Cephalon Deal In FTC Pay-For-Delay Suit
• Inspire Pharma Pays $5.9M To End FCA Suit Over Eye Drug
• La. Appeals Court Backs Novartis In Schizophrenia Drug Suit
• M&A Stokes Red-Hot Life Sciences IPO Market
• Where Do We Stand One Year After Alice?
• Blank Rome Adds Former Surgeon As IP Partner In New York
• Insulet Hit With Securities Suit Over Insulin Pump Claims
• Ex-NFL Player Can't Revisit Pump-And-Dump Verdict
• FTC Pushes 1st Circ. To Revive Loestrin Pay-For-Delay Suit
• Fed. Circ. Backs Celgene Win In Teva Cancer Drug Patent Suit
• Botox Maker Allergan Pays $2.1B For Aesthetics Co. Kythera
• Hill-Rom To Pay $2B For Medical Device Maker Welch Allyn
• New China FDA Guidance May Speed Up Device Approvals
• Mayo Test Dooms Breakthrough Biotech Invention
• 3rd Circ. Reiterates ERISA Allows 'Catalyst Theory' Fees
• Abbott Backs Mylan In Takeover Woes
• Voices Of The Bar: Meet The IP Experts
• AAI, Profs Push 1st Circ. To Overturn Pay-For-Delay Ruling
• Deals Rumor Mill: Houlihan Lokey, NCR, Coty
• Liberty Medical Makes Push For Ch. 11 Plan Confirmation
• Design Defect Claims Go Forward in Ethicon Mesh MDL
• Calif. Judge Boots Last Suit In Accutane Litigation
• Microbiome Biotech Seres Sets Terms For $106M IPO
• $17B Merck-Sigma Deal Gets EU Nod After Antitrust Fixes
• Diagnostics Co. Lantheus Seeks $83M In Revived IPO
• The High Court's Impact On Drug Disposal Ordinances
• 16 Cos. Polish $2.8B In IPO Plans
• 10th Circ. Lifts Injunction On Utah Contact Lens Pricing Law
• Even Breakthrough Patents Can Be Invalid, Sequenom Shows
• Bayer Downplays IUD Birth Control Safety Risks, Suit Claims
• Calif. Court Upholds Medtronic Spinal Fusion Suit Transfer
• J&J Attys, Witnesses Can't Reveal Own Tylenol Use: Plaintiffs
• Generic-Drug Makers Urge Changes To User-Fee Law
• Home Depot, GNC Among 25 Sued Over Site Search Patent
• Cohen Seglias Merges With Thaler Liebeler Amid DC Launch
• Gilead Defective Drug FCA Suit Tossed For Second Time
• Trustee Cut From J&J Heir's Tax Case Against Proskauer Rose
• J&J Can't Escape False Ad Suit Over 'Natural' Sweetener
• Plaintiffs Say Expert Overcomes Objections In Zoloft MDL
• Allergan Seeks 3rd Circ. Take On 'Critical' FCA Questions
• Tips To Avoid Conflicts When Hiring In-House Lawyers
• Glaucoma Device Maker Glaukos Sets Terms For $80M IPO
• Fried Frank, Dechert Guide CVS' $1.9B Target Pharmacy Buy
• Belgian Biotech Celyad Targets $99M US IPO
• Dish Worker's Firing For Medical Pot Use Deemed Lawful
• Is UK Pharmacy Legislation A Step Forward?
• Tech, Biotech Take Center Stage As 10 IPOs Target $1.6B
• Patient Wins $4.5M In First Wright Hip Implant Trial
• Pa. Zoloft Verdict Dims Plaintiffs' Hopes In MDL Expert Row
• India Fines GSK, Sanofi $10M For Anti-Competitive Plot
• Medical Device Co. Invuity Hits Slashed Terms In $48M IPO
• McKesson Nabs $6B DOD Pharmaceutical Deal Extension
• Pfizer Fights To Keep Expert In Zoloft Birth Defect MDL
• Teva Gets Nod For $24M Nexium Pay-For-Delay Settlement
• Judge Warns Axiom To Fix Fees Bid In Trademark Spat
• Amarin Decision Opens Door To Longer Exclusivity Periods
• Fed. Circ. Nixes Fetal DNA Test Patent Under Myriad, Mayo
• Why Law Firms Collapse
• Big Pharma Torches FDA In Amarin's Free Speech Suit
• Protein Powder Co. Says It Meets FDA Rules In False Ad Case
• Branch Law Firm Waived Fee Arbitration, Houston Court Hears
• Provigil Antitrust Cert. Bid Doomed By Inability To ID Class
• Health Care-Focused Joint Venture Lands $192M For 1st Fund
• Prosensa Investors Urge Redo On Suit Over Failed Drug
• Deals Rumor Mill: Apollo, GE, Alstom, Novartis
• Melinta Raises $67M In Venture Capital For New Drug
• Parkinson's-Focused Biotie's US IPO Hits Increased Target
• Philly Jury Clears Pfizer In 2nd Zoloft Birth Defect Case
• Dementia Drugmaker Axovant Draws $315M In Upsize IPO
• Goldwater Sues FDA For Access To Ebola Drug Docs
• 8 Product-Hopping Takeaways From Namenda Ruling
• Fed. Circ. Says Judge Erred In Defining Kaneka IP Claims
• Bayer Gets Preliminary Nod For $4.5M Cipro Antitrust Deal
• 1st Circ. Told Not To Focus On Cash In Loestrin Pay-For-Delay
• Vermont, German Ski Equipment Cos. In Patent Row
• Bayer Sells Diabetes Unit For $1B To Panasonic
• Intec Becomes Latest Parkinson's Drug Maker To Eye IPO
• Darvocet Failure To Warn Mass Action Transferred To Ky.
• Zoloft Birth Defect Case Heads To Philly Jury
• IRS, Ex-Employees Blast Liberty Medical's Ch. 11 Plan
• Teva Trades Kirkland For Sullivan & Cromwell In Mylan Bid
• Olympus Convinces PTAB To Nix 2 Electrosurgery Patents
• China Biologic Nabs $315M In Upsized Follow-On Offering
• First Databank Escapes Ranbaxy's Acne Med Libel Suit
• Covington Snags Pharmaceutical Policy Adviser
• Medical Marijuana And Gaming: How Close Is Too Close?
• Judge Recommends Blocking Kirkland From Repping Teva
• Axis Needn't Defend Advertising Co. In Fraud Suit: Judge
• Eli Lilly Pushes To Toss Cymbalta Withdrawal Suits
• Medtronic Escapes 3 Shareholder Suits Over Infuse Device
• 2nd Circ. Boots Medtronic Infuse Suit For Overstepping FDA
• Bayer Must Face FCA Claims Over Off-Label Trasylol Marketing
• Brokers Plead Guilty To Insider Trading In Ardea Biosciences
• JPML Centralizes Contact Lens Antitrust Actions In Florida
• Groups Tell 4th Circ. Bard Evidence Was Rightly Excluded
• Newman Can't Save Investors In SEC Insider Trading Case
• DC Circ. Upholds FTC's Pharma Patent Rules
• Actavis, Others Plotted To Delay Generic Namenda, Suit Says
• Is Your Pharmacy Ready For Drug Supply Chain Integrity?
• Bohai Pharma Hit With Suit Claiming Securities Shenanigans
• BioScrip Can't Hide Behind Omnicare In Securities Suit
• FDA Looks To Placate Amarin, Duck Free Speech Decision
• FDA Panel To Further Examine Amgen Cholesterol Drug
• Sex Bias Plaintiffs Fight Merck's Bid For Depositions
• Mom Says She'd Have Stopped Zoloft If Warned Of Risks
• Pfizer Plaintiffs Defend Robbins Geller Fees In $400M Deal
• Hedge Fund Hits Another Horizon Patent With AIA Review Bid
• FTC, Bayer Duel As Probiotics Promo Trial Nears
• Drug Development Service Patheon Eyes $100M US IPO
• FTC Asks For Quick Appeal Of AbbVie Pay-For-Delay Defeat
• Patent Applicants, Overlook Enablement At Your Peril
• 9th Circ. Says Alphatec Securities Action Was Weak
• FDA Panel To Give New Sanofi Cholestrol Drug A Closer Look
• Where Pay-For-Delay Stands 2 Years After Actavis
• NIH Suspends Drugmaking Facility After Fungal Contamination
• Actavis Asks 2nd Circ. To Rehear Namenda Antitrust Case
• Squire Patton Boggs Snags Ex-Fish & Richardson Principal
• Full Fed. Circ. Won't Review $61M Enzo Patent Ruling
• June IPO Market Chugs Forward As 6 Cos. Target $500M
• Cook Group Scores Win In Pelvic Mesh Suit
• Zoloft Caused Baby's Heart Defect, Expert Tells Philly Jury
• Standing Snafu Sinks Prosthetic Patent Row, Fed. Circ. Says
• A-Rod's Cousin Gets 7 Mos. For Role In MLB Doping Scandal
• Merck Whistleblowers Demand More Info On Mumps Vaccine
• Globus Fights J&J Unit's $16M Patent Win At Fed. Circ.
• EndoChoice Draws $95M In IPO At Low End Of Range
• Illumina Makes Arbitration Plea In IP Row Over DNA Testing
• Cardinal Health Pays $1.1B For Generics Distributor
• Congress' Bipartisan Revival Opens Health Policy Doors
• Calif. Ruling Backs Actos Pay-For-Delay Suit, Buyers Say
• The Rise Of Companion Diagnostics In Personalized Medicine
• CR Bard Gets Medical Implant Liability Suit Trimmed
• FDA Advisers Back Sprout's Drug To Boost Female Sex Drive
• European Biotechs Catch US IPO Fever
• CR Bard Gets Mesh Implant Suit Trimmed
• Nexium Buyers Say Namenda Ruling Supports Injunction Bid
• Greenberg Traurig Guides Opko In $1.47B Buy For Lab Co.
• AbbVie Rips 'Unsound' FDA Stand On Biosimilar Labels
• Mayer Brown Lures Food And Drug Partner From Jones Day
• Patent Dance Takes Center Stage In Amgen V. Sandoz Appeal
• Not All Claim Constructions Get Teva Deference: Fed. Circ.
• Cephalon Must Face Most Of FCA Off-Label Marketing Suit
• Catalent's PE Backers Draw $406M In Secondary Offering
• Puma Hit With Stock Drop Suit Over Breast Cancer Drug
• Boston Scientific Wants To Ax $34M Pelvic Mesh Judgment
• WHO Herbicide Cancer Study Worries US Corn, Soy Industries
• Amgen Says ACA Requires Sandoz To Disclose Biosimilar Info
• Teva, Others Seek To Nix Retailers' Pay-For-Delay Suits
• SEC, Feds Charge 4 Men For $4M Insider Trading Scheme
• Cystic Fibrosis Drugmaker Nivalis Sets Terms For $64M IPO
• 4th Circ. Told To Uphold $2M Bard Mesh Bellwether Verdict
• Class Tries Again For Cert. In Cymbalta Withdrawal Suit
• Health Plans Lose Provigil Pay-For-Delay Class Cert Bid
• Dendreon Gets Nod For Ch. 11 Liquidation Plan
• New FDA Rule Curbs Antibiotic Use In Animals
• Orrick Adds Ex-Davis Polk Atty Who Advised On Pandora IPO
• Pfizer Came Up Short On Zoloft Warnings, Expert Says
• Honigman Opens In Chicago With Schopf & Weiss Merger
• Alaska AG Wants To Ax Lupin Pay-For-Delay Probe Challenge
• AGs Urge FDA To Improve Dietary Supplement Regulation
• CytRx Settles Investor Claims Over 'Spring-Loaded' Options
• Prenatal Diagnostics Co. Natera Eyes $100M IPO
• House Committee Targets FDA's 'Untitled Letter' Discipline
• Prometheus Pushes Fed. Circ. To Revive IBS Drug Patent
• States Want In On New Charges Against Novartis In Exjade Suit
• 5 Insights From Schneider Electric GC Peter Wexler
• House Tax Panel Approves Medical Device Tax Repeal Bill
• Your Trademark Could Be A False Advertisement
• Sheller Tries To Stop FDA Bid To End Risperdal Doc Suit
• Wright Hip Implant Faulty, Jury Told In First Of 1,200 Cases
• Ethicon Severs Malpractice Claims From Pelvic Mesh Suit
• Fla. Compounding Pharmacy Pays $3.8M To Settle FCA Suit
• Surgical Lighting Device Co. Invuity Sets $73.6M IPO Terms
• Mylan Slams Teva For 'Playing Games' With Takeover Bid
• Novartis Sues Apotex Over Planned Zometa Generic
• Tyco's ANDA Suit Against Mutual Was Legit, Court Finds
• FDA Signals Tougher Approach To Animal Drug Compounding
• FCC Wants Feedback On Endo, AEP Fax Rule Waiver Requests
• Zoloft Caused Heart Defects In Newborn, Philly Jury Hears
• Merck Prevails In Former Exec's Pregnancy Bias Suit
• Hiscock, Damon Morey Merge Into Upstate NY's Largest Firm
• Philips Didn't Interfere With Worker's Other Job, 6th Circ. Says
• Axovant Sciences Sets Terms For $269M IPO
• PE-Backed 3SBio Seeks $711M In Hong Kong IPO